JP2021522345A5 - - Google Patents
Info
- Publication number
- JP2021522345A5 JP2021522345A5 JP2021509963A JP2021509963A JP2021522345A5 JP 2021522345 A5 JP2021522345 A5 JP 2021522345A5 JP 2021509963 A JP2021509963 A JP 2021509963A JP 2021509963 A JP2021509963 A JP 2021509963A JP 2021522345 A5 JP2021522345 A5 JP 2021522345A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- subject
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662637P | 2018-04-25 | 2018-04-25 | |
| US62/662,637 | 2018-04-25 | ||
| PCT/US2019/029192 WO2020033019A2 (en) | 2018-04-25 | 2019-04-25 | Novel mct4 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522345A JP2021522345A (ja) | 2021-08-30 |
| JP2021522345A5 true JP2021522345A5 (OSRAM) | 2022-04-28 |
| JP7115671B2 JP7115671B2 (ja) | 2022-08-09 |
Family
ID=68532786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509963A Active JP7115671B2 (ja) | 2018-04-25 | 2019-04-25 | 新規なｍｃｔ４阻害剤及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10919878B2 (OSRAM) |
| EP (1) | EP3784650B1 (OSRAM) |
| JP (1) | JP7115671B2 (OSRAM) |
| CN (1) | CN112888673B (OSRAM) |
| AU (1) | AU2019317518B2 (OSRAM) |
| CA (1) | CA3098189C (OSRAM) |
| WO (1) | WO2020033019A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12544375B2 (en) * | 2019-09-05 | 2026-02-10 | The Board Of Trustees Of The Leland Junior University | Small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity |
| WO2021249969A1 (en) * | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
| US20240270749A1 (en) | 2021-05-21 | 2024-08-15 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use |
| WO2022243574A1 (en) | 2021-05-21 | 2022-11-24 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1226438A (OSRAM) | 1968-12-03 | 1971-03-31 | ||
| GB0327734D0 (en) * | 2003-11-28 | 2003-12-31 | Novartis Ag | Organic compounds |
| TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| WO2010089580A1 (en) * | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
| CN102731413A (zh) * | 2011-04-15 | 2012-10-17 | 上海医药工业研究院 | 一种脲类化合物、其制备方法、其中间体及其应用 |
| WO2014189152A1 (en) | 2013-05-24 | 2014-11-27 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer |
| JP2017538689A (ja) | 2014-11-17 | 2017-12-28 | ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | モノカルボン酸輸送修飾薬およびその使用 |
| WO2016118822A1 (en) * | 2015-01-22 | 2016-07-28 | The Scripps Research Institute | Chromenone inhibitors of monocarboxylate transporters |
| WO2016118823A1 (en) | 2015-01-22 | 2016-07-28 | The Scripps Research Institute | Pteridine dione monocarboxylate transporter inhibitors |
| AU2016277126A1 (en) * | 2015-06-12 | 2017-12-14 | Vettore, LLC | MCT4 inhibitors for treating disease |
| AU2017444054B2 (en) * | 2017-12-21 | 2021-10-07 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Class of pyrimidine derivative kinase inhibitors |
-
2019
- 2019-04-25 AU AU2019317518A patent/AU2019317518B2/en active Active
- 2019-04-25 WO PCT/US2019/029192 patent/WO2020033019A2/en not_active Ceased
- 2019-04-25 JP JP2021509963A patent/JP7115671B2/ja active Active
- 2019-04-25 EP EP19847325.8A patent/EP3784650B1/en active Active
- 2019-04-25 CN CN201980035699.6A patent/CN112888673B/zh active Active
- 2019-04-25 CA CA3098189A patent/CA3098189C/en active Active
- 2019-04-25 US US16/395,099 patent/US10919878B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512175A5 (OSRAM) | ||
| JP2019503365A5 (OSRAM) | ||
| JP2023512174A5 (OSRAM) | ||
| JP2008521928A5 (OSRAM) | ||
| CN113767106A (zh) | 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2024507938A5 (OSRAM) | ||
| RU2016141934A (ru) | Ингибиторы циклин-зависимой киназы 7 (cdk7) | |
| JP2022515197A5 (OSRAM) | ||
| JP2005525345A5 (OSRAM) | ||
| JP2018526376A5 (OSRAM) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| JP2016518437A5 (OSRAM) | ||
| JP2015508103A5 (OSRAM) | ||
| FI3429571T3 (fi) | Lsd1-inhibiittorien yhdistelmiä käytettäväksi kasvaintautien hoitamisessa | |
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| JP2021530453A5 (OSRAM) | ||
| JP2015511609A5 (OSRAM) | ||
| JP2017530171A5 (OSRAM) | ||
| JP2016502981A5 (OSRAM) | ||
| EA201300420A1 (ru) | Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид | |
| JPWO2023195530A5 (OSRAM) | ||
| JP2015537009A5 (OSRAM) | ||
| JP2016501838A5 (OSRAM) |